Tomorrow review

Tomorrow publishes more of its care structure than an anonymous storefront: it identifies a medical group, names pharmacy partners and shows monthly and quarterly semaglutide billing. The main trade-off is commitment timing. An order becomes noncancelable when medical review begins, and subscription processing can precede the nominal renewal date. Read those boundaries before choosing the longer billing interval.

Tomorrow is a telehealth platform operated by Tomorrow Health LLC. Its terms identify Arora Health & Aesthetics, LLC as a medical group available through the service and distinguish Tomorrow from the healthcare provider. The About and Compliance pages name VialsRX for compounded injectables and The Pharmacy Hub for sublingual and brand-name medications. The terms allow other available licensed pharmacies and groups, so a published partner name does not guarantee the assignment for a particular order.

Tomorrow describes itself as new. The useful evidence is its published company and care structure, rather than an assumed long treatment history. Those disclosures do not independently verify professional licenses, product testing or an individual clinician’s suitability.

The process starts with an online medical intake reviewed by a clinician. The About page says review is usually without a call, but some states or medications require video or phone consultation. The semaglutide page says a clinician can ask for more information or recent lab results before deciding. It advertises one consultation covering the GLP-1 options, with the clinician selecting what is appropriate.

The service says a patient is charged only once a prescription is written; if the clinician declines treatment, no charge is made and a selected subscription is canceled. That advertised no-approval rule does not create a change-of-mind cancellation window after review begins.

An approved prescription is typically shipped within two business days according to the product page; that describes shipping, not guaranteed delivery by a particular date.

The compounded semaglutide page lists $199 billed monthly or $549 billed every three months, displaying $183 per month for the quarterly option. The latter is a three-month charge expressed as an average, not a $183 monthly payment. The advertised package includes prescription medication, injection supplies, consultation/review, ongoing clinician oversight and shipping. General terms describe a single subscription total that collects service, medical-group and pharmacy amounts where applicable. The cancellation policy also allows applicable taxes, shipping or service fees disclosed at checkout, so confirm the selected total rather than assuming the price card overrides every checkout condition.

Tomorrow is self-pay and says it does not bill insurance or government programs. Its page advertises pay-over-time options, but their financing terms are separate from the merchant’s quarterly billing.

The catalog also lists tirzepatide, microdose, sublingual and branded products; the $199/$549 figures here apply to the reviewed compounded semaglutide listing, not that entire menu.

The semaglutide product page describes an injection compounded with glycine by a 503A pharmacy. This is a merchant product description, not a finding that the additive improves results or makes the medicine equivalent to a branded pen. Tomorrow states that compounded medications are not FDA-approved.

Its catalog separately advertises compounded tirzepatide, lower-dose GLP-1 products, sublingual products and brand-name pens, alongside longevity products such as NAD+ and sermorelin. A broad menu does not establish that every option is suitable or available in every state. Confirm the prescribed formulation, quantity, concentration and supplying pharmacy. Product photographs are illustrative; the selected prescription and dispensing label should identify what is actually supplied.

The additional catalog listings are not a substitute for checking each product’s own price, supply and terms.